Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 4, 2018JNCI Journal of the National Cancer InstituteOpen Access

Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

RSReith SarkarMemorial Sloan Kettering Cancer CenterNGNicholas J. GloudeUniversity of San DiegoDSDeborah SchiffUniversity of California System

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sarkar et al. (2018) studied this question.

synapsesocial.com/papers/6a11ffdfae8fb4569ad208e4https://doi.org/10.1093/jnci/djy193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia2016 · 81 citations
  2. 2Hospital costs of pediatric intensive care1999 · 98 citations
  3. 3The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia2010 · 42 citations
  4. 4Cancer's Next Frontier2010 · 156 citations
  5. 5Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 20022013 · 349 citations